Skye Bioscience To Acquire Redx Pharma; Combined Company To Operate As Fibrx Therapeutics With $125M Financing
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor
Two smaller medicine companies are joining together to become one bigger company called Fibrx Therapeutics, and they got $125 million in money to help them work on treatments for a disease called fibrosis. When companies merge, watch to see if they can actually work well together and if their new medicine works in tests.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.